Gatadi Srikanth

Gatadi Srikanth

Auto-generated profile, based on publicly available information

Gatadi Srikanth

GITAM School of Pharmacy, GITAM Deemed to be University, Hyderabad campus, Telangana, India

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 April 2025 in Clinical and Translational Science
Verified
Journal Article
Open access
GSGatadi Srikanth
Gatadi Srikanth
DBDurga Prasad Beda
Durga Prasad Beda
ADAshish Ranjan Dwivedi
Ashish Ranjan Dwivedi
NDNandan Kumar Duddukuri
Nandan Kumar Duddukuri
SNSrinivas Nanduri
Srinivas Nanduri
JPJITENDRA PATEL
JITENDRA PATEL
TIGIT (T cell immunoreceptor with immunoglobulin and tyrosine‐based inhibitory motif (ITIM) domain), Vstm3, and VSIG9, are newly recognized immunological checkpoints. They are prominently expressed on CD4+ and CD8+ T cells, tumor‐infiltrating lymphocytes (TILs), natural killer (NK) cells, and regulatory T cells (Tregs). The TIGIT (TIGIT) protein is crucial for immune modulation since it diminishes NK cell populations and hinders T cell activity in cancer patients and experimental models. CD155, the principal ligand of TIGIT in humans, has been recognized as a pivotal target for immunotherapy owing to its interaction with TIGIT. CD155 is linked to the efficacy of anti‐programmed cell death protein 1 (PD‐1) therapy, even without TIGIT expression, underscoring its importance in immune checkpoint suppression. Anti‐TIGIT medicines, either independently or in conjunction with anti‐PD‐1 treatments, have demonstrated potential in augmenting immune responses to malignancies. This review examines the structural and functional characteristics of the TIGIT protein, new developments in anti‐TIGIT drugs, and their prospective use in cancer immunotherapy.

1 January 2026 in Current Topics in Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
SRSagar Rout
Sagar Rout
Katarina BauerovaKatarina Bauerova
Katarina Bauerova
BSBhabani Sankar Satapathy
Bhabani Sankar Satapathy
SGSrikanth Gatadi
Srikanth Gatadi
VMVasavi Malkhed
Vasavi Malkhed
Introduction: Routine synthetic chemo-drugs for the treatment of glioma exhibit limited blood-brain barrier (BBB) permeation and unavoidable serious neuronal toxicity with substandard treatment outcomes, which necessitates the exploration of novel, efficacious yet healthy tissuefriendly entities having the desired physicochemical characteristics with effective anticancer potential. Methods: ADMET analysis to investigate drug-likeness and toxicity profile of alpha-terpineol, followed by characterization of selected proteins. In silico studies, such as molecular docking and molecular simulation studies , were employed. Further, to validate the in silico results, an in vitro MTT assay and an in-vitro antioxidant study were carried out. Results: ADMET analysis showed promising results. Alpha-terpineol docked preferentially with selected glioma proliferation proteins, having a good docking score (>8). Reasonable antioxidant and cytotoxicity activity (IC50 18.3±1.1 μg/ml) was observed from DPPH and MTT assays . Discussion: The present study confirmed the potential anti-inflammatory, antioxidant, and anticancer effects of AT, which were further supported by in vitro study results. ADME analysis showed favourable drug-likeness of AT with desirable BBB permeation characteristics. AT was found to be potentially toxic to C6 glioma cells, whereas negligibly toxic to healthy neuronal cells. Conclusion: The outcomes of the study provide supportive evidence to proceed with further in vivo testing of AT in glioma models to establish it as a potent, efficacious anticancer drug.

30 April 2025 in Asian Journal of Chemistry
Verified
Journal Article
Open access
PDF file
GSGatadi Srikanth
Gatadi Srikanth
KRKaranam Santoshachandra Rao
Karanam Santoshachandra Rao
BSBhabani Sankar Satapathy
Bhabani Sankar Satapathy
PTParul Thapar
Parul Thapar
DBDurga Prasad Beda
Durga Prasad Beda
JPJITENDRA PATEL
JITENDRA PATEL
The COVID-19 pandemic has necessitated diverse therapeutic approaches, including drug-free therapies to complement pharmaceutical interventions. This review examines the current landscape, challenges and future perspectives of non-drug therapies for COVID-19. Critical approaches include oxygen therapy, mechanical ventilation, prone positioning, physical therapy, nutritional support, psychological support, hydration management and alternative therapies such as acupuncture and phototherapy. Despite their potential, these therapies face significant challenges, including disease variability, resource limitations, patient-specific factors, infection control issues and the need for robust clinical evidence. Future perspectives highlight the technological advancements such as telehealth, wearable devices and artificial intelligence; improved respiratory support systems; integrated multidisciplinary care; extensive public health initiatives; stringent clinical trials; personalized medicine; global health equity; mental health integration; lifestyle modifications and preparedness for future pandemics. Addressing these challenges and leveraging advancements will enhance the effectiveness and accessibility of drug-free therapies, improving patient outcomes and bolstering healthcare resilience against future pandemics.